- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc ...

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE’ Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER’ trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will ...

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company's president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024. Ms. Ricciardi also will host one-on-one investor meetings during which she will highligh ...

PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, supports Lewy Body Dementia Awareness Month and the critical need for more attention, research, and treatments for people with dementia with Lewy bodies (DLB). DLB is the second most common form of progressive dementia, affecting approximately 1.4 million people in the U.S., with no approved treatments ...

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company's president and CEO, Lisa Ricciardi will participate in two investor conferences in September. September 2024 Investor Conferences Event: Chardan Capital Markets Leadership Call Date/Time: September 5, 2024, at 11:00am ET Livestream: Individuals interested in attending the l ...

PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company's lead candidate for the treatment of Alzheimer's disease, were published in The Journal of Prevention of Alzheimer's Disease. SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Al ...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q2 2024 Earnings Conference Call August 11, 2024 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, LLC Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Daniil Gataulin - Chardan Operator Hello, and thank you for standing by. At this ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40886 Cognition Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 13-4365359 ...

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 - - Company to Host Investor Conference Call at 8:30 a.m. - Purchase, NY – August 8, 2024 – Cognition The ...

PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating ...